External beam radiation therapy with or without short-term androgen deprivation showed 15-year survival benefits for ...

Unrelated cord blood transplant demonstrated efficacy in patients with blood cancer after microcystic adnexal carcinoma.

Darolutamide may offer greater benefits than enzalutamide or apalutamide for Black and White patients with non-metastatic ...

Real-world data highlight gaps in genetic testing and targeted therapy use for metastatic castration-resistant prostate ...

During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed goals and barriers to treatment when using ...

The addition of 177Lu-PSMA-617 to enzalutamide significantly improved overall survival and QOL in patients with metastatic ...

During a Case-Based Roundtable® event, Neeraj Agarwal, MD, and participants discussed how they might determine which ...

One concern with bispecific antibody therapies in community settings is managing adverse events, with emerging patterns ...

Talazoparib plus enzalutamide boosts overall survival in metastatic castration-resistant prostate cancer, with HRR-deficient ...

Evan Y. Yu, MD, discusses other ongoing investigations exploring combinations based on radium-223 (Ra-223), highlighting ...

What does the Desmoid Tumor Working Group recommend for patients with potential desmoid tumors? 1. Nam Quoc Bui, MD: The ...

Mariam F. Eskander, MD, MPH, and Coral O. Omene, MD, PhD, discuss potential strategies that teams can implement to ensure clinical trials are more representative of the general population.